Loading clinical trials...
Loading clinical trials...
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergo...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Massachusetts General Hospital
Collaborators
NCT05463263 · Lymphoma, B-Cell, Lymphoma, T-Cell
NCT06678659 · Unresectable, Locally Advanced, and more
NCT03418038 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, and more
NCT06875063 · Non-hodgkin Lymphoma, Refractory Lymphoma, and more
NCT07188558 · Large B-cell Lymphoma, Lymphoma, B-Cell, and more
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions